BE2014C019I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C019I2 BE2014C019I2 BE2014C019C BE2014C019C BE2014C019I2 BE 2014C019 I2 BE2014C019 I2 BE 2014C019I2 BE 2014C019 C BE2014C019 C BE 2014C019C BE 2014C019 C BE2014C019 C BE 2014C019C BE 2014C019 I2 BE2014C019 I2 BE 2014C019I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0012890 | 2000-12-18 | ||
| PCT/EP2001/014182 WO2002053557A1 (en) | 2000-12-18 | 2001-12-04 | Novel sulfamides and their use as endothelin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2014C019I2 true BE2014C019I2 (ru) | 2021-01-29 |
Family
ID=8164206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2014C019C BE2014C019I2 (ru) | 2000-12-18 | 2014-03-11 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7094781B2 (ru) |
| EP (2) | EP1693372A1 (ru) |
| JP (1) | JP4245130B2 (ru) |
| KR (1) | KR100819668B1 (ru) |
| CN (1) | CN100432070C (ru) |
| AR (1) | AR035610A1 (ru) |
| AT (1) | ATE323079T1 (ru) |
| AU (1) | AU2002227984B8 (ru) |
| BE (1) | BE2014C019I2 (ru) |
| BR (1) | BRPI0116237B8 (ru) |
| CA (1) | CA2431675C (ru) |
| CY (2) | CY1105060T1 (ru) |
| DE (1) | DE60118782T2 (ru) |
| DK (1) | DK1345920T3 (ru) |
| ES (1) | ES2260318T3 (ru) |
| FR (1) | FR14C0017I2 (ru) |
| HU (1) | HU229403B1 (ru) |
| IL (2) | IL155805A0 (ru) |
| LU (1) | LU92381I2 (ru) |
| MX (1) | MXPA03004780A (ru) |
| MY (1) | MY129150A (ru) |
| NL (1) | NL300672I2 (ru) |
| NO (2) | NO324952B1 (ru) |
| NZ (1) | NZ525614A (ru) |
| PT (1) | PT1345920E (ru) |
| WO (1) | WO2002053557A1 (ru) |
| ZA (1) | ZA200303695B (ru) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ525614A (en) * | 2000-12-18 | 2005-03-24 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| EP2198867A1 (en) | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
| EP1569914B1 (en) * | 2002-12-02 | 2009-02-18 | Actelion Pharmaceuticals Ltd. | Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
| KR100822530B1 (ko) | 2004-03-05 | 2008-04-16 | 에프. 호프만-라 로슈 아게 | Ｐ2ｘ3 및 ｐ2ｘ2/3 길항물질로서의 다이아미노피리미딘 |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| TW200628467A (en) * | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| TW200745061A (en) | 2005-07-29 | 2007-12-16 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis C virus |
| PL1913015T3 (pl) | 2005-07-29 | 2014-04-30 | Janssen R&D Ireland | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
| EP1924564B1 (en) | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| CN101253159B (zh) | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物 |
| JP4850913B2 (ja) | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３及びｐ２ｘ２／３調節因子としてのジアミノピリジン |
| WO2007031933A2 (en) * | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| AR062501A1 (es) * | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) * | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| EP2199283A1 (en) | 2007-09-27 | 2010-06-23 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient |
| SI2254570T1 (sl) * | 2008-02-20 | 2014-03-31 | Actelion Pharmaceuticals Ltd. | Kombinacija, obsegajoča paklitaksel, za zdravljenje raka na jajčnikih |
| NO2315587T3 (ru) * | 2008-08-13 | 2018-03-24 | ||
| US8791090B2 (en) | 2009-03-31 | 2014-07-29 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient |
| TWI483938B (zh) | 2009-08-10 | 2015-05-11 | Univ Texas | 以內皮素受體抑制劑處理星狀腫瘤細胞 |
| US9567318B2 (en) | 2009-08-17 | 2017-02-14 | Memorial Sloan-Kettering Cancer Center | Substituted pyrimidine compounds and uses thereof |
| WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| EA201391131A1 (ru) | 2011-02-04 | 2013-12-30 | Актелион Фармасьютикалз Лтд. | Сочетания с мацитентаном для лечения полиморфной глиобластомы |
| CA2902252A1 (en) * | 2013-03-15 | 2014-09-18 | Monique Bodil Van Niel | Aryl sulfamide and sulfamate derivatives as rorc modulators |
| AR095727A1 (es) * | 2013-03-27 | 2015-11-04 | Actelion Pharmaceuticals Ltd | Preparación de intermediarios de pirimidina |
| DE14721256T1 (de) | 2013-04-22 | 2017-03-16 | Sandoz Ag | Pharmazeutische zusammensetzungen mit kristallinem macitentan |
| CN105693624B (zh) * | 2013-06-14 | 2018-05-18 | 杭州普晒医药科技有限公司 | 马西替坦晶体及其制备方法、其药物组合物和用途 |
| AR096865A1 (es) * | 2013-07-12 | 2016-02-03 | Actelion Pharmaceuticals Ltd | Proceso para la preparación de un intermediario de pirimidina |
| CN103724281A (zh) * | 2013-12-03 | 2014-04-16 | 镇江圣安医药有限公司 | N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用 |
| EP2907811A1 (en) | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| CN103819411A (zh) * | 2014-03-14 | 2014-05-28 | 成都克莱蒙医药科技有限公司 | 一种马西替坦中间体新的制备方法 |
| JP6607870B2 (ja) | 2014-05-13 | 2019-11-20 | メモリアル スローン ケタリング キャンサー センター | Ｈｓｐ７０モジュレーターならびにその作製および使用方法 |
| WO2016009322A1 (en) * | 2014-07-15 | 2016-01-21 | Sifavitor S.R.L. | Amorphous form and new crystalline forms of macitentan |
| CN104447572A (zh) * | 2014-12-15 | 2015-03-25 | 南京艾德凯腾生物医药有限责任公司 | 一种马西替坦的制备方法 |
| WO2016203489A1 (en) | 2015-06-15 | 2016-12-22 | Megafine Pharma (P) Ltd. | Process for the preparation of macitentan and intermediates thereof |
| ZA201605808B (en) | 2015-08-26 | 2017-08-30 | Cipla Ltd | Process for preparing an endothelin receptor antagonist |
| CN105461639B (zh) * | 2015-12-10 | 2018-03-09 | 合肥久诺医药科技有限公司 | 一种高纯度马西替坦的精制方法 |
| CN105388244B (zh) * | 2015-12-10 | 2017-03-08 | 合肥久诺医药科技有限公司 | 一种马西替坦有关物质的高效液相色谱分析方法 |
| WO2017191565A1 (en) * | 2016-05-04 | 2017-11-09 | Shilpa Medicare Limited | Process for preparation of macitentan |
| CN107868055B (zh) * | 2016-09-28 | 2020-02-07 | 普济生物科技（台州）有限公司 | 一种马西替坦的制备方法 |
| CN106478520B (zh) * | 2016-10-11 | 2018-09-11 | 合肥久诺医药科技有限公司 | 一种马西替坦杂质标准品的合成方法 |
| CN106478522A (zh) * | 2016-10-11 | 2017-03-08 | 合肥久诺医药科技有限公司 | 一种马西替坦杂质标准品的制备方法 |
| CN110325186A (zh) | 2017-02-27 | 2019-10-11 | 爱杜西亚药品有限公司 | 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与活性成分的组合 |
| EP3606913B1 (en) | 2017-04-03 | 2022-04-27 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| CN107141238A (zh) * | 2017-06-16 | 2017-09-08 | 吴宁怡 | 一种马西替坦中间体的制备方法 |
| RS64040B1 (sr) * | 2017-11-21 | 2023-04-28 | Wuxi Biocity Biopharmaceutics Co Ltd | Derivat pirimidin sulfamida i njegov postupak dobijanja i primena u medicini |
| CA3083327A1 (en) | 2017-11-30 | 2019-06-06 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| CN108653292B (zh) * | 2018-07-03 | 2019-05-24 | 中国人民解放军总医院 | 一种化合物在治疗或预防高原病中的用途 |
| CN108997223B (zh) * | 2018-08-09 | 2020-06-30 | 浙江先锋科技股份有限公司 | 5-(4-溴苯基)-4，6-二氯嘧啶的制备方法 |
| CN109232546B (zh) * | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
| JOP20210153A1 (ar) | 2018-12-21 | 2023-01-30 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية لعلاج ارتفاع ضغط الدم الشرياني الرئوي |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
| FI3974421T3 (fi) * | 2019-05-22 | 2024-09-24 | Wuxi Biocity Biopharmaceutics Co Ltd | Pyrimidiinisulfoniamidiyhdisteen kidemuoto ja sen valmistusmenetelmä |
| MX2022000267A (es) | 2019-07-05 | 2022-02-03 | Tecnimede Soc Tecnico Medicinal Sa | Composiciones comprimidas de macitentan, metodos y usos de las mismas. |
| JP2023504115A (ja) | 2019-11-29 | 2023-02-01 | アクテリオン ファーマシューティカルズ リミテッド | 肺動脈性肺高血圧症の治療方法 |
| WO2022258796A1 (en) | 2021-06-11 | 2022-12-15 | Actelion Pharmaceuticals Ltd | Dispersible tablet for oral administration |
| EP4154873A1 (en) | 2021-09-22 | 2023-03-29 | Sanovel Ilac Sanayi Ve Ticaret A.S. | The tablet comprising macitentan |
| WO2023227490A1 (en) | 2022-05-22 | 2023-11-30 | Idorsia Pharmaceuticals Ltd | Aprocitentan for the treatment of hypertension |
| WO2023227721A1 (en) | 2022-05-25 | 2023-11-30 | Idorsia Pharmaceuticals Ltd | Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide |
| WO2024099953A1 (en) | 2022-11-07 | 2024-05-16 | Actelion Pharmaceuticals Ltd | Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2801584A1 (de) * | 1978-01-14 | 1979-07-19 | Bayer Ag | Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide |
| US5132373A (en) * | 1990-08-13 | 1992-07-21 | General Electric Company | Ortho ester-capped polyphenylene ethers and copolymers prepared therefrom |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US5324796A (en) * | 1992-12-02 | 1994-06-28 | General Electric Company | Polyarylene sulfide and epoxy-functionalized siloxane blends |
| TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| US5523204A (en) | 1993-12-10 | 1996-06-04 | Becton Dickinson And Company | Detection of nucleic acids in cells by strand displacement amplification |
| WO1996016963A1 (de) * | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
| TW313568B (ru) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| EP0882719B1 (en) | 1995-12-20 | 2001-05-16 | Yamanouchi Pharmaceutical Co. Ltd. | Arylethenesulfonamide derivatives and drug composition containing the same |
| TWI284642B (en) * | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
| ATE380180T1 (de) * | 1999-09-03 | 2007-12-15 | Actelion Pharmaceuticals Ltd | Bis-sulfonamiden |
| JP2003518102A (ja) * | 1999-12-22 | 2003-06-03 | アクテリオン ファマシューティカルズ リミテッド | ブチンジオール誘導体 |
| AU2001263850A1 (en) * | 2000-04-20 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Pyrimidine-sulfonamides having endothelin-antagonist activity |
| AU2001265871A1 (en) * | 2000-04-25 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
| NZ525614A (en) * | 2000-12-18 | 2005-03-24 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
-
2001
- 2001-12-04 NZ NZ525614A patent/NZ525614A/en not_active IP Right Cessation
- 2001-12-04 CA CA2431675A patent/CA2431675C/en not_active Expired - Lifetime
- 2001-12-04 KR KR1020037008013A patent/KR100819668B1/ko active Protection Beyond IP Right Term
- 2001-12-04 MX MXPA03004780A patent/MXPA03004780A/es active IP Right Grant
- 2001-12-04 WO PCT/EP2001/014182 patent/WO2002053557A1/en active IP Right Grant
- 2001-12-04 JP JP2002554676A patent/JP4245130B2/ja not_active Expired - Lifetime
- 2001-12-04 AU AU2002227984A patent/AU2002227984B8/en active Active
- 2001-12-04 EP EP06007371A patent/EP1693372A1/en not_active Withdrawn
- 2001-12-04 CN CNB018204813A patent/CN100432070C/zh not_active Expired - Lifetime
- 2001-12-04 BR BRPI0116237A patent/BRPI0116237B8/pt active IP Right Grant
- 2001-12-04 PT PT01989570T patent/PT1345920E/pt unknown
- 2001-12-04 US US10/433,041 patent/US7094781B2/en active Active
- 2001-12-04 HU HU0301654A patent/HU229403B1/hu active Protection Beyond IP Right Term
- 2001-12-04 IL IL15580501A patent/IL155805A0/xx active IP Right Grant
- 2001-12-04 AT AT01989570T patent/ATE323079T1/de active
- 2001-12-04 DK DK01989570T patent/DK1345920T3/da active
- 2001-12-04 DE DE60118782T patent/DE60118782T2/de not_active Expired - Lifetime
- 2001-12-04 ES ES01989570T patent/ES2260318T3/es not_active Expired - Lifetime
- 2001-12-04 EP EP01989570A patent/EP1345920B1/en not_active Expired - Lifetime
- 2001-12-14 AR ARP010105818A patent/AR035610A1/es active IP Right Grant
- 2001-12-14 MY MYPI20015700A patent/MY129150A/en unknown
-
2003
- 2003-05-08 IL IL155805A patent/IL155805A/en active Protection Beyond IP Right Term
- 2003-05-13 ZA ZA200303695A patent/ZA200303695B/en unknown
- 2003-06-13 NO NO20032699A patent/NO324952B1/no not_active IP Right Cessation
-
2006
- 2006-04-07 US US11/400,697 patent/US7285549B2/en not_active Expired - Lifetime
- 2006-06-27 CY CY20061100879T patent/CY1105060T1/el unknown
-
2014
- 2014-02-26 LU LU92381C patent/LU92381I2/xx unknown
- 2014-03-03 FR FR14C0017C patent/FR14C0017I2/fr active Active
- 2014-03-11 BE BE2014C019C patent/BE2014C019I2/fr unknown
- 2014-04-11 CY CY2014017C patent/CY2014017I2/el unknown
- 2014-06-05 NO NO2014014C patent/NO2014014I2/no not_active IP Right Cessation
- 2014-06-12 NL NL300672C patent/NL300672I2/nl unknown